Gestrinone and Endothelial Function in Young Women
Conditions: Hormones; Abuse; Cardiovascular Diseases Interventions: Other: Hormonal implant Sponsors: Hospital Israelita Albert Einstein Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 7, 2024 Category: Research Source Type: clinical trials
The Association Between Food Timing and Composition on Gastrointestinal Injury, Stress Hormone and Gastrointestinal Complains.
Conditions: Endothelial Dysfunction Interventions: Other: 2000 meter ergometer test Sponsors: Poznan University of Physical Education Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 7, 2024 Category: Research Source Type: clinical trials
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Conditions: Osteoporosis; Osteoporosis, Steroid Induced; Inflammatory Rheumatism Interventions: Drug: Glucocorticoid Effect Sponsors: Diakonhjemmet Hospital; Vestre Viken Hospital Trust; Hormone Laboratory, Aker University Hospital, Oslo, Norway Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 2, 2024 Category: Research Source Type: clinical trials
" Quick-starting " of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition
Conditions: Ultrasound Finding: Ovulation Inhibition, Ovarian Activities; Cervical Mucus; Serum Hormonal Profile Interventions: Drug: Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2); Drug: Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7) Sponsors: Chulalongkorn University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 2, 2024 Category: Research Source Type: clinical trials
" Quick-starting " of a New Combined Hormonal Contraceptive Pills, 15 mg Estetrol/3 mg Drospirenone VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition
Conditions: Ultrasound Finding: Ovulation Inhibition, Ovarian Activities; Cervical Mucus; Serum Hormonal Profile Interventions: Drug: Estetrol 15 mg/Drospirenone 3 mg (24/4); Drug: Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7) Sponsors: Chulalongkorn University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 2, 2024 Category: Research Source Type: clinical trials
Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Deleterious HRR Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK2 Gene Mutation; FANCA Gene Mutation; PALB2 Gene Mutation; RAD51B Gene Mutation; RAD54L Gene Mutation Interventions: Drug: Androgen deprivation therapy (ADT); Drug: Niraparib/Abiraterone Acetate; Drug: Abiraterone acetate; Drug: Prednisone; Drug: Docetaxel Sponsors: Qian Qin; UT Southwestern Comprehensive Cancer Center; Janssen, LP Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
Conditions: Prostate Cancer Interventions: Drug: hyperpolarized pyruvate +/-urea (13C/15N); Radiation: Non-investigational Stereotactic body radiotherapy (SBRT); Procedure: Radiotherapy (RT); Procedure: Multi-parametric magnetic resonance imaging (mpMRI); Biological: Non-interventional hormone therapy; Procedure: Prostate Biopsy Sponsors: Robert Bok, MD, PhD; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Conditions: Prostate Cancer; Prostate Adenocarcinoma; Hormone Sensitive Prostate Cancer Interventions: Radiation: Para Aortic Radiation Therapy: Photon Therapy; Radiation: Para Aortic Radiation Therapy: Proton Therapy; Drug: Androgen Deprivation Therapy; Drug: Androgen Receptor Signaling Inhibitor Sponsors: University of Miami Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials
Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer
Conditions: Prostate Adenocarcinoma Interventions: Diagnostic Test: PSMA PET/CT Sponsors: Peking University First Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials
DiviTum ®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Conditions: HER2-negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Metastatic Breast Cancer Interventions: Procedure: Biospecimen Collection Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials
A Bioavailability Study of Two Different PEG-rhGH Preparations.
Conditions: Pediatric Growth Hormone Deficiency (PGHD) Interventions: Drug: PEG-rhGH with new preparation (T); Drug: PEG-rhGH with present preparation (R) Sponsors: Changchun GeneScience Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
Conditions: Idiopathic Short Stature Interventions: Drug: Vosoritide Injection; Drug: Human Growth Hormone; Drug: Placebo Sponsors: BioMarin Pharmaceutical Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Conditions: Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; ESR1 Gene Mutation Interventions: Drug: Everolimus; Drug: Elacestrant; Drug: Placebo; Drug: Auxiliary Medicinal Product - Dexamethasone; Drug: Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues Sponsors: MedSIR; Stemline Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compared to Placebo in Patients With Thin Endometrium Undergoing Frozen Thawed Embryo Transfer
Conditions: Thin Endometrium; Infertility Female; Infertility Interventions: Drug: Growh hormone; Other: Placebo Sponsors: Isfahan University of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Conditions: Recurrent Castration-Sensitive Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer Interventions: Drug: Abiraterone; Drug: Apalutamide; Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Drug: Darolutamide; Drug: Degarelix; Drug: Enzalutamide; Drug: Goserelin; Drug: Histrelin; Drug: Leuprolide; Procedure: Magnetic Resonance Imaging; Other: Patient Observation; Procedure: Positron Emission Tomography; Drug: Prednisone; Other: Questionnaire Administration; Drug: Relugolix; Radiation: Stereotactic Body Radiatio...
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
